Last reviewed · How we verify

NCT05771727

Impact of Covid-19 Pandemic on Children With Neuromuscular Disease and Their Parents in Turkey: Parent Perspective

Completed Last updated 16 March 2023
What this trial tests

trial testing survey in Neuromuscular Diseases in 134 participants. Completed in 1 October 2021.

Timeline
1 July 2021
Primary endpoint
1 August 2021
1 October 2021

Quick facts

Lead sponsorHacettepe University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment134
Start date1 July 2021
Primary completion1 August 2021
Estimated completion1 October 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Hacettepe University

Who can join

Eligibility, any sex, with Neuromuscular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Parents of children with neuromuscular disease have been already at risk of depression, anxiety and burden. Additionally, the daily lives of children with neuromuscular disease and their parents have been significantly affected by the COVID-19 pandemic. Therefore, this study investigated parents' perspective on the effect of the COVID-19 pandemic on children with neuromuscular diseases and themselves.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of survey

Trials testing the same drug.

Other recruiting trials for Neuromuscular Diseases

Currently open trials in the same condition.

Other Hacettepe University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05771727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing